Le Lézard
Classified in: Environment, Transportation, Covid-19 virus
Subjects: ENI, ENP

Air Treatment Solution for Public Transit Approved by EPA to Provide Continuous Protection Against COVID-19


RAHWAY, NJ and PLANO, TX, Jan. 19, 2021 /PRNewswire/ -- The U.S. Environmental Protection Agency (EPA) approved a Section 18 Public Health Emergency Exemption for the use of Grignard Puretm, an antimicrobial air treatment solution, for intrastate transit and transportation applications. Administered through Luminator Technology Group's (Luminator) Renewtm Air Treatment System, the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.

Grignard Pure is expected to kill 98% of SARS-CoV-2 virus particles in the air, where transmission is most likely.

The EPA's Section 18 Emergency Exemption for Grignard Pure, which is effective for Georgia and Tennessee, applies to its use in approved indoor spaces (occupied and unoccupied) when adherence to current public health guidelines is impractical or difficult to maintain (e.g., CDC guidance at www.cdc.gov recommending social distancing, limited occupancy, and increased ventilation). Among the approved use sites are intrastate transportation as well as select approved health care and food processing facilities and indoor spaces within buildings?including government facilities?where people are conducting activity deemed essential by the state and allowed by the state lead agency. The EPA is expected to approve additional exemptions for more states in the coming weeks.

When deployed in mass transit environments, the system will help protect passengers, operators and other transit employees from the spread of the virus that causes COVID-19. Grignard Pure is dispensed on-board transit bus and rail vehicles through an adaptive system, manufactured by Luminator, a global leader in transit technology and communication solutions.

Grignard Pure is expected to kill 98% of SARS-CoV-2 virus particles in the air, where transmission is most likely. When in use, it delivers continuously effective protection of indoor occupied and unoccupied spaces, including transit buses and railcars.

"As public health officials work to recover national and local economies, public transportation continues to play a vital role," said Etienne Grignard, co-founder and CEO of Grignard Pure. "The EPA approval of Grignard Pure allows entities in these states to deploy science-based technology solutions to enhance safety. Through this partnership with Luminator, it will help protect transit riders and operators."

Luminator's Renew Air Treatment System dispenses the antimicrobial air treatment through a connected, technologically advanced system that measures and automatically adjusts the amount of Grignard Pure that is dispensed. As conditions change with the opening of doors when passengers embark and disembark the vehicle, the system maintains an effective level to kill 98% of COVID-19 airborne virus particles.

"With the pandemic causing tremendous disruption to the public transportation industry, we are proud to help support its recovery with a combination of science and innovation," said Kirk Goins, CEO of Luminator Technology Group. "In partnership with Grignard Pure, we are providing riders, transit employees, and operators the assurance they need to return to work and help passengers reach their destinations safely and efficiently. We expect the implementation of the Renew Air Treatment System will make a lasting impact on restoring ridership, safety, and confidence."

"Those of us in public and environmental health have learned much about the properties and behaviors of the virus over the past nine months, as we continue to develop and recommend best practices for responding as a society," said Dr. Jack Caravanos, clinical professor of environmental health sciences at New York University's School of Public Health, and a member of the independent and uncompensated Grignard Pure Science Advisory Team. "I've worked closely with the Grignard Pure team since April to assure the effectiveness of the solution. Adding Grignard Pure to a safety protocol, including personal hygiene, masks and social distancing, is a critical step toward helping to restore the social, cultural and business norms we enjoyed pre-pandemic."

For more information about Grignard Pure, including a full list of approved use sites and access to safety and efficacy reports, visit www.GrignardPure.com.

About Grignard Pure
Grignard Pure, LLC, founded in 2020, is based in New Jersey. It was, until recently, a subsidiary of Grignard Company, LLC, a manufacturer of atmospheric effect solutions founded in 1963. For more information, visit www.GrignardPure.com.

About Luminator Technology Group
Luminator Technology Group (Luminator) is a leading manufacturer of stationary and on-board passenger information systems, video security, air treatment and lighting solution for global mass transportation applications. The company, founded in 1928, leverages its extensive engineering resources to develop solutions that increase intelligence, safety and efficiency for bus, rail and aerospace operations worldwide. For more information, visit www.luminator.com.

SOURCE Luminator Technology Group


These press releases may also interest you

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

18 avr 2024
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...



News published on and distributed by: